| First Author | Davies DM | Year | 2021 |
| Journal | Cancer Cell | Volume | 39 |
| Issue | 2 | Pages | 138-140 |
| PubMed ID | 33417830 | Mgi Jnum | J:302329 |
| Mgi Id | MGI:6508325 | Doi | 10.1016/j.ccell.2020.12.019 |
| Citation | Davies DM, et al. (2021) Crosstown Traffic: Lymphodepleting Chemotherapy Drives CAR T Cells. Cancer Cell 39(2):138-140 |
| abstractText | CAR-engineered T cell immunotherapy has proven transformative in selected hematological malignancies. However, solid tumors largely remain impervious to these approaches. In addressing this challenge, Srivastava et al. in this issue demonstrate that oxaliplatin-based lymphodepleting chemotherapy promotes enhanced CAR T cell recruitment to lung tumors, boosting therapeutic impact in combination with anti-PD-L1. |
